HLDF-6
A synthetic hexapeptide (TGENHR) derived from the HLDF protein, investigated preclinically for neuroprotection in Alzheimer's and Parkinson's models.
HLDF-6 is a synthetic hexapeptide corresponding to a fragment of the human leukemia differentiation factor (HLDF) protein, with the sequence TGENHR. It has been studied in rodent and cell-based models for neuroprotective properties, where it is proposed to reduce neuroinflammation, protect against beta-amyloid toxicity, and attenuate dopaminergic neuron loss. Its evidence base is entirely preclinical; no human clinical trials, pharmacokinetic studies, or safety evaluations have been indexed in PubMed, and no regulatory authority has evaluated or approved it for any indication.
Class
Synthetic hexapeptide (HLDF protein fragment)
Routes
Intranasal, Subcutaneous
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Neuroprotection
In preclinical models HLDF-6 is proposed to protect neurons against oxidative stress-induced damage and reduce neuroinflammation. Evidence is limited to rodent and cell-based studies.
Reduced amyloid-beta toxicity
HLDF-6 has been investigated in transgenic Alzheimer's disease models where it is proposed to reduce beta-amyloid toxicity and associated neuronal injury at the cellular and behavioral level.
Memory enhancement
It may enhance memory consolidation, hypothesized to occur via upregulation of the acetylcholine pathway and modulation of cholinergic neurotransmission. This remains a mechanistic hypothesis supported only by animal data.
Dopaminergic protection
In MPTP-induced Parkinson's disease models, HLDF-6 is proposed to attenuate dopaminergic neuron loss, suggesting cognitive- and motor-protective potential in preclinical settings.
Anti-aging / cellular support
HLDF-6 is grouped with longevity and cellular-support research compounds, with proposed effects on inflammatory cytokines and oxidative stress pathways.
Mechanism
How it works
HLDF-6 (TGENHR) is a six-residue fragment of the human leukemia differentiation factor protein. Its proposed mechanism centers on modulation of cholinergic neurotransmission, with reported effects on the acetylcholine pathway that may support memory consolidation. It is also proposed to influence acetylcholinesterase activity.
In neurodegenerative disease models, HLDF-6 is hypothesized to reduce amyloid-beta toxicity and protect against oxidative stress-induced neuronal damage. It is proposed to modulate inflammatory cytokines and oxidative stress pathways, contributing to a broadly neuroprotective and anti-neuroinflammatory profile.
Preclinical work spans transgenic Alzheimer's models (targeting beta-amyloid toxicity and neuroinflammation) and MPTP-induced Parkinson's models (targeting dopaminergic neuron loss). All mechanistic claims derive from rodent and cell-based studies; the translation of these findings to human therapeutic outcomes has not been investigated.
Safety
Side effects & considerations
Contraindications & cautions
- Pregnancy or nursing
HLDF-6 is generally described as lower risk in research contexts, but no human safety evaluations have been conducted. Individual response varies and the compound is intended for research use only.
FAQ
HLDF-6 — common questions
What is HLDF-6?
HLDF-6 (human leukemia differentiation factor hexapeptide; TGENHR) is a synthetic hexapeptide derived from a sequence of the HLDF protein. It has been investigated in preclinical models for neuroprotective properties in conditions including Alzheimer's disease and Parkinson's disease, where it is proposed to reduce neuroinflammation, protect against beta-amyloid toxicity, and attenuate dopaminergic neuron loss.
What is HLDF-6 primarily studied for?
Neuroprotection, memory enhancement, cognitive support, and anti-aging, based on rodent and cell-based research.
How does HLDF-6 work?
It is proposed to modulate cholinergic neurotransmission and the acetylcholine pathway, reduce amyloid-beta toxicity, and protect against oxidative stress-induced neuronal damage, while modulating inflammatory cytokines and oxidative stress pathways. These are mechanistic hypotheses supported only by preclinical data.
Are there human clinical trials for HLDF-6?
No. No published human clinical trials, pharmacokinetic studies, or safety evaluations of HLDF-6 administration have been indexed in PubMed. Its entire evidence base consists of rodent and cell-based studies.
Is HLDF-6 approved or regulated?
No. HLDF-6 has no FDA approval or regulatory approval in any jurisdiction. It is a research-only neuroprotective compound that has not been evaluated by any regulatory authority.
What are the side effects of HLDF-6?
No human safety data exist. It is described as lower risk in research contexts, and the primary reported contraindication is pregnancy or nursing. Consult a qualified healthcare professional before any decision.
How is HLDF-6 administered in research?
The reported research administration routes are intranasal and subcutaneous.
